Jemincare Group Co., Ltd
http://www.jemincare.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jemincare Group Co., Ltd
Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
Roche Continues To Cast Its Collaborations Net Wide
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.
Chinese Pharma Looks To Out-Licensing As Domestic Downturn Bites
China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.
Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Shanghai Jemincare Pharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice